George Hemstreet, MD
Interventional Cardiology · Tuscaloosa, ALNPI 1851400485
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.0%), speaking fees and other — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Philips North America LLC at 43.1% of the total. Reporting peaked in 2021 at $13,065 and has fallen 74.2% since, to $3,374 in 2025.
Across 1,007 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$15K
- Angiodynamics, Inc.$5K
- Novartis$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Abbott$1K
- Johnson & Johnson$1K
- plus $9K from 49 others
What the payments were for
- Consulting fees$1,8805%
- Speaking & faculty fees$12,70536%
- Food & beverage$15,74545%
- Education$3031%
- Other$4,32012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,953 in reported general payments places this provider in the 85th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 135 | $1,854,058 |
| EliquisApixaban | 1,086 | $992,221 |
| UptraviSelexipag | 24 | $594,027 |
| AdempasRiociguat | 31 | $522,478 |
| MultaqDronedarone Hcl | 257 | $320,959 |
| EntrestoSacubitril/Valsartan | 295 | $301,256 |
| Repatha SureclickEvolocumab | 306 | $257,360 |
| XareltoRivaroxaban | 201 | $202,217 |
| JardianceEmpagliflozin | 134 | $99,906 |
| BrilintaTicagrelor | 139 | $88,406 |
| EdarbiAzilsartan Medoxomil | 102 | $43,480 |
| MounjaroTirzepatide | 32 | $31,979 |
| Ranolazine ErRanolazine | 284 | $30,241 |
| FarxigaDapagliflozin Propanediol | 43 | $27,143 |
| Nebivolol Hcl | 367 | $23,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,621 | $2,448,085159 claims |
| PfizerEliquis | $541 | $992,2211,086 claims |
| BayerAdempas | $79 | $522,47831 claims |
| Sanofi-aventis U.S. LLCMultaq | $797 | $320,959257 claims |
| NovartisEntresto | $2,010 | $301,256295 claims |
| Johnson & JohnsonXarelto | $1,091 | $202,217201 claims |
| AstraZenecaBrilinta, Farxiga | $318 | $115,548182 claims |
| Boehringer IngelheimJardiance | $230 | $99,906134 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $57 | $53,676118 claims |
| AmgenCorlanor | $942 | $8,83111 claims |
| Esperion Therapeutics, Inc.Nexlizet | $435 | $7,56519 claims |
| MerckVerquvo | $415 | $7,45211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Tuscaloosa
- Edward CarrawayTuscaloosa$8K
- William HillTuscaloosa$7K
- Lovdie LewisTuscaloosa$6K
- James ProctorTuscaloosa$6K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.